Technology about mRNA vaccine
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
- World first: An mRNA vaccine that can 100% protect against deadly bacterial infections is available
- The first successful use of CAR-T cells to treat severe muscle inflammation
Technology about mRNA vaccine
- More than 1 million Chinese died after China quit “Zero-COVID policy”?
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Technology about mRNA vaccine. ModeRNA, which also uses mRNA vaccine technology, has developed a new coronavirus vaccine code-named mRNA-1273.
On March 16, the ModeRNA vaccine completed its first injection in Seattle, the United States, becoming the world’s first human trial of a COVID-19 vaccine.
What kind of technology is mRNA vaccine?
mRNA (messenger RNA) is a single-stranded ribonucleic acid that translates proteins in cells.
Only 4 days after identifying the pathogen of the new coronavirus, Chinese scientists announced the full sequence of the new coronavirus genome to the world. Three days after the sequence was published, Barney Graham of the National Institute of Allergy and Infectious Diseases (NIAID) calculated the best target for the vaccine—Spike Protein.
It is precisely because of these two unprecedented speeds that the development of mRNA vaccines is progressing rapidly.
Researchers can directly modify and edit the RNA segment of the translation target protein through the published RNA sequence of the new coronavirus (for example: Pfizer uses the method of 1-methyl-pseudouridine modification) to obtain a segment that can produce antigen RNA fragments of proteins.
After this piece of RNA is injected into the body, the body’s somatic cells produce a large number of antigen proteins on their own, causing a specific immune response.
Source: BioNTech 2020/4 BNT162 latest progress
In theory, this method can make people resist. The mRNA that enters the human body can further guide the translation of the antigen protein, and degrade it in the body after the guidance is completed. But theory is theory after all. mRNA vaccine technology has appeared as early as the 1990s.
The reason why it has not replaced traditional vaccine technology is that it is very restricted by technology, the nature of mRNA itself and many other factors.
Ordinary vaccines (inactivated virus or antigen protein, etc.) are generally stable and can reach the body by intravenous injection, but the mRNA itself is very unstable and easily degraded.
Pfizer uses liposome encapsulation technology to make mRNA into nanoparticles, which “disguise” vaccines as viruses. After injection, the vaccine enters the cell through endocytosis and releases the mRNA in the nanoparticle in the cell, thereby exerting the role of mRNA.
In this way, the problem of rapid degradation of mRNA after entering the human body can be solved. Judging from the results of phase I, II, and III clinical trials currently published, this program has received data support.
Disclaimer of medicaltrend.org